Fintel reports that on January 28, 2026, Barclays initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Overweight recommendation.
Analyst Price Forecast Suggests 16.86% Upside
As of January 14, 2026, the average one-year price target for BridgeBio Pharma is $90.56/share. The forecasts range from a low of $68.11 to a high of $115.50. The average price target represents an increase of 16.86% from its latest reported closing price of $77.49 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BridgeBio Pharma is 586MM, an increase of 65.72%. The projected annual non-GAAP EPS is -3.15.
What is the Fund Sentiment?
There are 725 funds or institutions reporting positions in BridgeBio Pharma. This is an increase of 4 owner(s) or 0.55% in the last quarter. Average portfolio weight of all funds dedicated to BBIO is 0.41%, an increase of 7.54%. Total shares owned by institutions decreased in the last three months by 2.72% to 213,192K shares. 
The put/call ratio of BBIO is 0.61, indicating a bullish outlook.
What are Other Shareholders Doing?
Viking Global Investors holds 15,978K shares representing 8.29% ownership of the company. In its prior filing, the firm reported owning 18,555K shares , representing a decrease of 16.13%. The firm decreased its portfolio allocation in BBIO by 6.95% over the last quarter.
Kohlberg Kravis Roberts & Co. holds 13,261K shares representing 6.88% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 8,741K shares representing 4.54% ownership of the company. In its prior filing, the firm reported owning 9,277K shares , representing a decrease of 6.13%. The firm decreased its portfolio allocation in BBIO by 59.32% over the last quarter.
Farallon Capital Management holds 8,192K shares representing 4.25% ownership of the company. In its prior filing, the firm reported owning 7,900K shares , representing an increase of 3.56%. The firm increased its portfolio allocation in BBIO by 18.35% over the last quarter.
Aisling Capital Management holds 6,090K shares representing 3.16% ownership of the company. In its prior filing, the firm reported owning 6,068K shares , representing an increase of 0.35%. The firm decreased its portfolio allocation in BBIO by 4.88% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
